Key result
Hemochron Jr. closely correlates with laboratory aPTT and yields results ~53 minutes faster.
Why the study?
A new microsample coagulation analyzer (Hemochron Jr.) was developed to provide rapid and reproducible ACT and aPTT measurements using small blood volumes, but its clinical performance compared to existing techniques needed evaluation.
Does the Hemochron Jr. microsample coagulation analyzer provide comparable and faster ACT and aPTT measurements compared to standard techniques in patients undergoing coronary intervention?
Observational (n=44)
Does the Hemochron Jr. microsample coagulation analyzer provide comparable and faster ACT and aPTT measurements compared to standard techniques in patients undergoing coronary intervention?
Effect estimate: r = 0.79
p-value: p=<0.0001
The Hemochron Jr. microsample coagulation analyzer provides rapid and reproducible ACT and aPTT measurements that correlate well with standard techniques during coronary interventions.
May support faster anticoagulation monitoring in PCI; leaves open impact on safety or outcomes.
A new microsample coagulation analyzer (Hemochron Jr.) has recently been developed which performs a modified activated clotting time (ACT+) and an aPTT by using different reagents. The Hemochron Jr. measures the clotting time of a 5-microliter whole-blood sample by an optical detector and extrapolates the results to the activated clotting time (ACT+) or the plasma-activated partial thromboplastin time by using a validated regression analysis. We compared 124 simultaneous ACT+ and Hemochron ACTs, and 53 paired Hemochron Jr. aPTTs and hospital laboratory aPTTs, in 44 patients during coronary intervention. The Hemochron Jr. aPTT closely correlated with the lab aPTT (r = .79, P < .0001), and the test results were available much more rapidly than the lab aPTT (3.5 +/- 1.1 vs. 56.3 +/- 25.5 min, P = 0.0029). A comparison of duplicate ACT+ measurements did not identify a significant difference in the means (292 +/- 115 sec vs. 293 +/- 112 sec, P = 0.72). The ACT+ closely correlated with the Hemochron ACTs (r = .85, P < .0001). At baseline, the mean ACT+ (175 +/- 43 sec) exceeded the Hemochron ACT (144 +/- 36 sec) by 22% (P < .001). After heparin administration, the mean ACT+ (378 +/- 74 sec) exceeded the Hemochron ACT (332 +/- 65) by 12% (P < .001). The Hemochron Jr. provides a fast and reproducible methodology for measuring ACT and aPTT, using a small blood volume. Further studies are required to determine the optimal anticoagulation range when using the Hemochron Jr. during or after interventional procedures.
No takes yet. Share an insight, caveat, or question.
Carter et al. (1996) conducted an observational in Coronary intervention (n=44). Hemochron Jr. microsample coagulation analyzer vs. Hospital laboratory aPTT and standard Hemochron ACT was evaluated on Correlation between Hemochron Jr. aPTT and hospital laboratory aPTT (r = 0.79, p=<0.0001). The Hemochron Jr. microsample coagulation analyzer aPTT closely correlated with laboratory aPTT (r = 0.79, P<0.0001) and yielded faster results (3.5 vs 56.3 min, P=0.0029).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: